CoreWeave EVP Chen Goldberg sells $678,790 in shares on Aug. 17

CoreWeave EVP Chen Goldberg sells $678,790 in shares on Aug. 17

CoreWeave EVP Chen Goldberg sells $678,790 in shares on Aug. 17
Key insights: Seventeen banks, including BNY, Citi, HSBC, Standard Chartered and Wells Fargo, are preparing to test live, tokenized cross-border payments on the company’s blockchain-based orchestration platform. What’s at stake: The transition to a pilot stage is an important step for Swift as the rise of digital assets threaten its position as a key coordinator…
The combined pre-sales of 11 leading listed residential developers in India are projected to rise to ₹1.82 lakh crore in FY27 from ₹1.49 lakh crore in FY26, marking a 22.3% increase, according to an analysis by ANAROCK Research of investor presentations. The projected growth comes despite higher property prices, elevated construction costs…
13 August 2026 Overall, 92% of companies with physical points of sale accept cash Cash acceptance rebounds after decline observed during and after pandemic Cash widely valued for privacy and reliability, while acceptance of mobile payments rises sharply According to the latest survey on the use of cash by companies in the euro area published…
The TactaBot™ combines the company’s Tacta Hand, Skill Capture, and “Dexterous Intelligence” AI engine to bring human-level dexterity and touch to robotics for the first time. The Tacta Hand delivers unprecedented dexterity, precision, strength, and industrial-grade reliability over millions of cycles, finally unlocking high-value tasks for robotics. The company will deploy the technology with best-in-class…
Treasury yields and oil prices surged, and the dollar confirmed the breakout toward a longer-term uptrend, to push the S&P 500 below key chart support.
(RTTNews) – Dermata Therapeutics, Inc. (DRMA) announced financial results for the second quarter ended June 30, 2026, alongside a corporate update highlighting its transition into a commercial-stage skincare company. The San Diego-based firm is preparing to launch its first direct-to-consumer product, Tome Foundational Treatment, on August 25, 2026. Second quarter results showed a net loss…